Travere Gains 11% on Securing Full FDA Nod for Kidney Disease DrugZacks Investment Research • 09/09/24
Travere Stock Pops After Snagging Full Approval For Calliditas Rival In Kidney DiseaseInvestors Business Daily • 09/06/24
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA NephropathyBusiness Wire • 09/06/24
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA NephropathyGlobeNewsWire • 09/05/24
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024GlobeNewsWire • 08/22/24
Strength Seen in Travere (TVTX): Can Its 8.8% Jump Turn into More Strength?Zacks Investment Research • 07/10/24
Travere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual ConferenceGlobeNewsWire • 07/08/24
Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association CongressGlobeNewsWire • 05/09/24
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA NephropathyGlobeNewsWire • 04/24/24
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA NephropathyPRNewsWire • 04/24/24
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians InternationalGlobeNewsWire • 04/04/24
Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses AssociationGlobeNewsWire • 04/03/24
Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)GlobeNewsWire • 03/11/24
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA NephropathyGlobeNewsWire • 02/23/24
CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathyPRNewsWire • 02/23/24